AU2020343725A1 - Cancer treatment - Google Patents

Cancer treatment Download PDF

Info

Publication number
AU2020343725A1
AU2020343725A1 AU2020343725A AU2020343725A AU2020343725A1 AU 2020343725 A1 AU2020343725 A1 AU 2020343725A1 AU 2020343725 A AU2020343725 A AU 2020343725A AU 2020343725 A AU2020343725 A AU 2020343725A AU 2020343725 A1 AU2020343725 A1 AU 2020343725A1
Authority
AU
Australia
Prior art keywords
compound
group
cancer
alkyl
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020343725A
Other languages
English (en)
Inventor
Tobias BALD
Michael BETTESS
Christophe Demaison
Francesca MERCURI
Christopher Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Axelia Oncology Pty Ltd
Original Assignee
Axelia Oncology Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2019903263A external-priority patent/AU2019903263A0/en
Application filed by Axelia Oncology Pty Ltd filed Critical Axelia Oncology Pty Ltd
Publication of AU2020343725A1 publication Critical patent/AU2020343725A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
AU2020343725A 2019-09-04 2020-09-04 Cancer treatment Pending AU2020343725A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2019903263 2019-09-04
AU2019903263A AU2019903263A0 (en) 2019-09-04 Cancer treatment
AU2019904863 2019-12-20
AU2019904863A AU2019904863A0 (en) 2019-12-20 Cancer treatment (2)
PCT/AU2020/050936 WO2021042174A1 (en) 2019-09-04 2020-09-04 Cancer treatment

Publications (1)

Publication Number Publication Date
AU2020343725A1 true AU2020343725A1 (en) 2022-03-24

Family

ID=74851931

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020343725A Pending AU2020343725A1 (en) 2019-09-04 2020-09-04 Cancer treatment

Country Status (5)

Country Link
US (1) US20220347146A1 (https=)
EP (1) EP4025203A4 (https=)
JP (1) JP2022546807A (https=)
AU (1) AU2020343725A1 (https=)
WO (1) WO2021042174A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2618842B1 (en) 2010-09-22 2019-04-24 Ena Therapeutics Pty Ltd Novel immunostimulatory method
AU2018391325B2 (en) 2017-12-21 2024-07-11 Axelia Oncology Pty Ltd Optimised compounds
MX2021015961A (es) 2019-06-26 2022-03-22 Ena Respiratory Pty Ltd Moleculas novedosas.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101151280A (zh) * 2005-02-08 2008-03-26 昆士兰医学研究学院委员会 免疫原性分子
GB0907989D0 (en) * 2009-05-08 2009-06-24 Hybrid Systems Ltd Multivalent adjuvant display
EP2618842B1 (en) * 2010-09-22 2019-04-24 Ena Therapeutics Pty Ltd Novel immunostimulatory method
CN113876945A (zh) * 2011-10-06 2022-01-04 免疫疫苗技术有限公司 包括激活或增加tlr2活性的佐剂的脂质体组合物及其应用
US20170274068A1 (en) * 2014-09-12 2017-09-28 The University Of Melbourne Immunological reagent
EP3328418A1 (en) * 2015-07-29 2018-06-06 Novartis AG Combination therapies comprising antibody molecules to pd-1
CN110461351B (zh) * 2017-03-31 2024-03-26 艾娜呼吸私人有限公司 用tlr2激动剂治疗呼吸道感染
AU2018391325B2 (en) * 2017-12-21 2024-07-11 Axelia Oncology Pty Ltd Optimised compounds
AU2020340468A1 (en) * 2019-09-04 2022-03-24 Axelia Oncology Pty Ltd Cancer immunotherapy

Also Published As

Publication number Publication date
EP4025203A1 (en) 2022-07-13
US20220347146A1 (en) 2022-11-03
WO2021042174A1 (en) 2021-03-11
EP4025203A4 (en) 2023-12-20
JP2022546807A (ja) 2022-11-09

Similar Documents

Publication Publication Date Title
US20210206787A1 (en) Prodrugs of glutamine analogs
RU2752729C2 (ru) Пролекарства альвоцидиба, имеющие повышенную биодоступность
US20230043518A1 (en) Cancer immunotherapy
AU2020343725A1 (en) Cancer treatment
JP7358342B2 (ja) 新規なグルタミンアンタゴニストおよびそれらの使用
US11008286B2 (en) Amino mercaptan compound and preparation method therefor and use thereof in protection against radiation
US20230257345A1 (en) Novel molecules
JP2013523599A (ja) 新規なオピオイドのジカルボン酸結合アミノ酸及びペプチドプロドラッグ並びにその用途
US20210230217A1 (en) Optimised compounds
ES2884357T3 (es) Modulación de la actividad de las citocinas gamma-c
ES2784703T3 (es) Derivados de la pirrolidina carboxamida y métodos para preparar y utilizar la misma
US20190083663A1 (en) Carbonic anhydrase ix targeting agents and methods
US20090264345A1 (en) Macrocyclic peptides and methods for making and using them
EP2010203A2 (en) Macrocyclic peptides and methods for making and using them
US20230372551A1 (en) Radiolabeled ligands for targeted pet/spect imaging and methods of their use
EP3811980A1 (en) Accumulative boron 10 medicine for boron neutron capture therapy for selectively or locally targeting tumor tissues in short time
US20240252693A1 (en) Folate receptor-targeted radiotherapeutic agents and their use
AU2020287607A1 (en) Modified peptides and associated methods of use
US20180125992A1 (en) Drug delivery conjugates of tertiary amine containing drugs
ES2318541T3 (es) Agente terapeutico util para el tratamiento de neoplasias de celulas plasmaticas.
US20260007758A1 (en) Somatostatin subtype-2 receptor (sst2r) non-peptide drug conjugates and uses thereof